- Home
- ITIC vs BDTX Comparison
ITIC vs BDTX Comparison
Compare ITIC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- BDTX
- Stock Information
- Founded
- ITIC 1972
- BDTX 2014
- Country
- ITIC United States
- BDTX United States
- Employees
- ITIC N/A
- BDTX N/A
- Industry
- ITIC Specialty Insurers
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITIC Finance
- BDTX Health Care
- Exchange
- ITIC Nasdaq
- BDTX Nasdaq
- Market Cap
- ITIC 440.1M
- BDTX 181.4M
- IPO Year
- ITIC N/A
- BDTX 2020
- Fundamental
- Price
- ITIC $250.81
- BDTX $3.16
- Analyst Decision
- ITIC
- BDTX Strong Buy
- Analyst Count
- ITIC 0
- BDTX 6
- Target Price
- ITIC N/A
- BDTX $12.50
- AVG Volume (30 Days)
- ITIC 26.3K
- BDTX 840.0K
- Earning Date
- ITIC 11-04-2025
- BDTX 11-04-2025
- Dividend Yield
- ITIC 6.21%
- BDTX N/A
- EPS Growth
- ITIC 25.49
- BDTX N/A
- EPS
- ITIC 17.49
- BDTX 0.25
- Revenue
- ITIC $269,460,000.00
- BDTX $70,000,000.00
- Revenue This Year
- ITIC N/A
- BDTX N/A
- Revenue Next Year
- ITIC N/A
- BDTX N/A
- P/E Ratio
- ITIC $14.24
- BDTX $12.78
- Revenue Growth
- ITIC 15.27
- BDTX N/A
- 52 Week Low
- ITIC $190.20
- BDTX $1.20
- 52 Week High
- ITIC $290.40
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- ITIC 58.04
- BDTX 58.90
- Support Level
- ITIC $248.67
- BDTX $3.13
- Resistance Level
- ITIC $257.39
- BDTX $3.43
- Average True Range (ATR)
- ITIC 4.77
- BDTX 0.18
- MACD
- ITIC -0.92
- BDTX 0.02
- Stochastic Oscillator
- ITIC 58.22
- BDTX 63.51
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.